The IL-23 inhibitor from AbbVie for patients 6 years of age and older with active psoriatic arthritis (PsA) or with moderate to severe plaque psoriasis (Ps) who are candidates for systemic therapy or phototherapy.¹

SUSTAINED JOINT SYMPTOM RELIEF

ACR20 achieved at Week 24 with response rates observed up to ~6 years^1-7

SELECT BASELINE CHARACTERISTICS IN SKYRIZI CLINICAL TRIALS^1-3

BIO-NAÏVE PATIENTS IN KEEPsAKE 1: SELECT BASELINE CHARACTERISTICS

KEEPsAKE 1 | SKYRIZI (n=483) AND PLACEBO (n=481) PATIENTS

Patients HAD
NO PRIOR USE
OF BIOLOGICS

~21
TENDER
JOINTS
AT BASELINE
(based on 68 joints),
mean

~12
SWOLLEN
JOINTS
AT BASELINE
(based on 66 joints),
mean

~61^%
OF PATIENTS WITH
PREEXISTING
ENTHESITIS
(LEI>0), %

~31^%
OF PATIENTS WITH
PREEXISTING
DACTYLITIS
(LDI>0), %

Age (years)
median (range)
SKYRIZI: 52 (20–85)
Placebo: 52 (22–79)

Sex
female, n (%)
SKYRIZI: 231 (48%)
Placebo: 247 (51%)

KEEPsAKE 2 | SKYRIZI (n=224)
AND PLACEBO (n=219) PATIENTS

PATIENTS WITH PREEXISTING
ENTHESITIS (LEI>0)

SKYRIZI:
66^%

Placebo: 72%

PATIENTS WITH PREEXISTING
DACTYLITIS (LDI>0)

SKYRIZI:
18^%

Placebo: 26%

IN KEEPsAKE 1 AND KEEPsAKE 2, THE PRIMARY ENDPOINT WAS ACR20 RESPONSE AT WEEK 24 (NRI‑C).^1-3

KEEPsAKE 1

57% SKYRIZI (n=483)
34% PLACEBO (n=481)

KEEPsAKE 2

51% SKYRIZI (n=224)
27% PLACEBO (n=219)

NON-RANKED SECONDARY ENDPOINTS WERE ACR50/70 RESPONSE AT WEEK 24 (NRI‑C).^1-3

KEEPsAKE 1

ACR50:
33% SKYRIZI (n=483)
11% PLACEBO (n=481)

ACR70: 15% SKYRIZI (n=483)
5% PLACEBO (n=481)

KEEPsAKE 2

ACR50:
26% SKYRIZI (n=224)
9% PLACEBO (n=219)

ACR70: 12% SKYRIZI (n=224)
6% PLACEBO (n=219)

DATA LIMITATIONS: Data labeled as a primary endpoint were multiplicity controlled for comparisons. All other comparisons were not adjusted for multiplicity; therefore, statistical significance has not been established.

STUDY DESIGN: KEEPsAKE 1 (N=964) and KEEPsAKE 2 (N=443) were 2 randomized, double-blind, placebo-controlled studies that evaluated the efficacy and safety of SKYRIZI 150 mg vs placebo over 24 weeks with a long-term, open-label extension for up to an additional 292 weeks. Both studies enrolled adult patients with active psoriatic arthritis. In KEEPsAKE 1, the study population had an inadequate response or intolerance to at least 1 csDMARD, while in KEEPsAKE 2 patients had an inadequate response or intolerance to at least 1 biologic therapy OR to at least 1 csDMARD.^1,4,5

SUSTAINED RELIEF IN JOINTS WITH RESULTS UP TO ~6 YEARS

ACR20/50/70 RESPONSE RATES FOR csDMARD-IR PATIENTS SUSTAINED AT ~6 YEARS^6,7

KEEPsAKE 1: csDMARD-IR | ALL DATA IS AS OBSERVED

KEEPsAKE 1 ACR20/50/70 response rates over ~6 years

AS OBSERVED (AO) ANALYSIS: Patients with missing data at a specific time are not included, which may enrich the population and increase the response rates.

OLE LIMITATIONS: An OLE may enrich long-term data, as patients intolerant or unresponsive to the drug drop out.

ACR20/50/70=improvement of at least 20%, 50%, or 70% in tender joint count, swollen joint count, and at least 3 other core criteria; csDMARD-IR=intolerance or inadequate response to conventional synthetic disease-modifying antirheumatic drug(s); NRI=nonresponder imputation; OLE=open-label extension; RCT=randomized controlled trial.

IMPROVEMENTS IN ACR COMPONENTS OF DISEASE ACTIVITY 
AT WEEK 24 (MMRM) AND ~6 YEARS (AO)^1,7

KEEPsAKE 1: csDMARD-IR

Swipe to scroll

	SKYRIZI (n=483)			Placebo (n=481)
	Baseline	Mean Change at Week 24 (RCT)	Mean Change at Week 304 (OLE)	Baseline	Mean Change at Week 24 (RCT)
Number of Swollen Joints (0-66)	12.1	-8.7	-11.1 (n=333)	12.2	-6.7
Number of Tender Joints (0-68)	20.8	-12.0	-17.5 (n=333)	20.5	-7.9
Patient’s Assessment of Pain (0-100 VAS)	57.1	-21.4	-28.9 (n=320)	57.1	-10.9
Patient’s Global Assessment of Disease Activity (0-100 VAS)	57.9	-22.6	-28.2 (n=320)	57.4	-11.1
Physician’s Global Assessment of Disease Activity (0-100 VAS)	61.3	-34.8	-51.2 (n=300)	62.4	-22.2
HAQ-DI* (0-3 scale, where 0=no difficulty, 3=inability to perform)	1.2	-0.3	-0.40 (n=320)	1.2	-0.1
hs-CRP (mg/L)	11.9	-4.3	-4.07 (n=310)	11.3	-0.2

DATA LIMITATION: Data labeled as a ranked secondary endpoint was multiplicity-controlled for comparisons. All other comparisons were not adjusted for multiplicity; therefore, statistical significance has not been established.

OLE LIMITATIONS: An OLE may enrich long-term data, as patients intolerant or unresponsive to the drug drop out.

AO ANALYSIS: Patients with missing data at a specific time are not included, which may enrich the population and increase the response rates.

*Week 24 ranked secondary endpoint.² 

ACR=American College of Rheumatology; AO=as observed; csDMARD-IR=intolerance or inadequate response to conventional synthetic disease-modifying antirheumatic drug(s); HAQ-DI=health assessment questionnaire disability index; hs-CRP=high-sensitivity C-reactive protein; MMRM=mixed-effect model for repeated measures; OLE=open-label extension; RCT=randomized controlled trial; VAS=visual analog scale.

DO YOUR PsA PATIENTS HAVE SKIN INVOLVEMENT?

See the sustained PASI 90 and PASI 100 response rates out to ~6 years⁷

VIEW PASI DATA

COMPLETE RESOLUTION OF ENTHESITIS & DACTYLITIS^2,†

ENTHESITIS RESOLUTION (LEI=0) ACHIEVED AT WEEK 24 (SKYRIZI 48%, n=444; PLACEBO 35%, n=448; P<0.001)^2,‡

DACTYLITIS RESOLUTION (LDI=0) ACHIEVED AT WEEK 24 (SKYRIZI 68%, n=188; PLACEBO 51%, n=204; P<0.001)^2,‡

^‡Pooled KEEPsAKE 1 and KEEPsAKE 2 data (NRI-C) (ranked secondary endpoints).

INTEGRATED RESULTS FROM KEEPsAKE 1: csDMARD-IR, AND KEEPsAKE 2: MIXED POPULATION (~50% csDMARD-IR, ~50% Bio-IR): LEI AND LDI OVER TIME^6,8

ALL DATA IS AS OBSERVED

% of SKYRIZI patients who achieved
COMPLETE RESOLUTION OF ENTHESITIS
(LEI=0)

At Week 24 (RCT)
52^% (n=426)

vs 42% with Placebo (n=416)

At Week 304 (OLE)

82^%

of patients experienced 
complete enthesitis 
resolution 
(n=279)

% of SKYRIZI patients who achieved
COMPLETE RESOLUTION OF DACTYLITIS
(LDI=0)

At Week 24 (RCT)
74^% (n=181)

vs 60% with Placebo (n=192)

At Week 304 (OLE)

97^%

of patients experienced 
complete dactylitis 
resolution 
(n=130)

OLE LIMITATIONS: An OLE may enrich long-term data, as patients intolerant or unresponsive to the drug drop out.

AS OBSERVED (AO) ANALYSIS: Patients with missing data at a specific time are not included, which may enrich the population and increase the response rates.

^†Resolution defined as Leeds Enthesitis Index=0 and Leeds Dactylitis Index=0. These measures were only evaluated in patients with involvement at baseline.

SKYRIZI vs OTEZLA® (apremilast)

In adult patients with moderate Ps⁹

SEE THE LATEST HEAD-TO-HEAD DATA

WELL-STUDIED SAFETY PROFILE

Across PsA & Ps¹

REVIEW THE SAFETY PROFILE

*The first n-value is for KEEPsAKE 1; the second n-value is for KEEPsAKE 2.
^†At Week 16, subjects classified as nonresponders (defined as not achieving at least a 20% improvement in either or both tender joint count and swollen joint count at both Week 12 and Week 16 compared to baseline) had the option to add or modify rescue concomitant medications/therapy. Starting at Week 36, subjects classified as nonresponders were discontinued from study drug.
^‡To maintain the blind to the original treatment at Week 24, subjects randomized to placebo received blinded SKYRIZI 150 mg, and subjects randomized to SKYRIZI received blinded placebo.

KEEPsAKE 1: csDMARD-IR. KEEPsAKE 2: Mixed population (~50% csDMARD-IR, ~50% Bio-IR)

csDMARD-IR population: Inadequate response (lack of efficacy after minimum 12-week duration of therapy) or intolerance to previous or current treatment with at least 1 csDMARD at maximally tolerated dose; Bio-IR population: Inadequate response (lack of efficacy after minimum 12-week duration of therapy) or intolerance to treatment with 1 or 2 biologic therapies intended to treat PsA

KEEPsAKE 1 (N=964) and KEEPsAKE 2 (N=443) were 2 randomized, double-blind, placebo-controlled studies that evaluated the efficacy and safety of SKYRIZI (150 mg) vs placebo over 24 weeks with an open-label extension for up to an additional 292 weeks in adult patients with active psoriatic arthritis.

In both studies, subjects were randomized to receive SKYRIZI 150 mg or placebo at Weeks 0, 4, and 16. Starting at Week 28, all subjects received SKYRIZI every 12 weeks. 59.6% of subjects from both studies received concomitant MTX, 11.6% received concomitant nonbiologic DMARDs other than MTX, and 28.9% received SKYRIZI monotherapy.

In both studies, similar responses were seen regardless of concomitant nonbiologic DMARD use, number of prior nonbiologic DMARDs, age, gender, race, and BMI.

In KEEPsAKE 2, responses were seen regardless of prior biologic therapy.

In KEEPsAKE 1, bilateral radiographs of hands and feet were included at screening, baseline, Week 24, Week 52, Week 100, Week 148, Week 196, and Week 244.

Primary endpoint

Proportion of subjects who achieved ACR20 response at Week 24

Ranked key secondary endpoints

Change from baseline in HAQ-DI at Week 24
Proportion of patients with PASI 90 at Week 24^a
Proportion of patients with ACR20 response at Week 16
Proportion of patients with MDA at Week 24
Change from baseline in mNAPSI at Week 24^b
Percentage of patients who achieved resolution of enthesitis at Week 24 (Pooled KEEPsAKE 1 and 2)^c
Percentage of patients who achieved resolution of dactylitis at Week 24 (Pooled KEEPsAKE 1 and 2)^d
Mean change in mTSS from baseline at Week 24

Non-ranked secondary endpoints

Proportion of patients who achieved ≥50% and ≥70% improvement in ACR50/70 at Week 24

Key inclusion criteria

≥18 years of age
Clinical diagnosis of PsA with symptom onset ≥6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) at the Screening Visit
Active disease defined as ≥5 tender joints and ≥5 swollen joints
Active plaque psoriasis with at least 1 psoriatic plaque of ≥2 cm diameter or nail changes consistent with psoriasis
KEEPsAKE 1: History of inadequate response or intolerance to at least 1 csDMARD therapy
KEEPsAKE 2: History of inadequate response or intolerance to 1 or 2 biologic therapies and/or csDMARD

^aIn the subset of subjects with a body surface area (BSA) ≥3% at baseline.
^bIn the subset of subjects with nail psoriasis at baseline.
^cIn the subset of subjects with enthesitis at the LEI sites at baseline.
^dIn the subset of subjects with dactylitis at the LDI sites at baseline.

ACR=American College of Rheumatology; ACR20/50/70=≥20%/50%/70% improvement in tender joint count, swollen joint count, and at least 3 other core criteria; Bio-IR=inadequate response or intolerance to a biologic; BMI=body mass index; csDMARD=conventional synthetic disease-modifying antirheumatic drug; csDMARD-IR=intolerance or inadequate response to conventional synthetic disease-modifying antirheumatic drug; DMARD=disease-modifying antirheumatic drug; HAQ-Dl=health assessment questionnaire disability index; LDI=Leeds Dactylitis Index; LEI=Leeds Enthesitis Index; MDA=minimal disease activity; mNAPSI=modified Nail Psoriasis Severity Index; mTSS=modified Total Sharp Score; MTX=methotrexate; OLE=open-label extension; PASI 90=≥90% improvement in Psoriasis Area and Severity Index; PsA=psoriatic arthritis.

REFERENCES

SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225-231. doi:10.1136/annrheumdis-2021-221019
Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351-358. doi:10.1136/annrheumdis-2021-221048
Kristensen LE, Keiserman M, Papp K, et al. Long-term efficacy and safety of risankizumab for csDMARD-IR patients with active psoriatic arthritis: 148-week results from the KEEPsAKE 1 trial. Poster presented at: American College of Rheumatology Convergence; November 10-15, 2023; San Diego, CA.
Östör A, Van den Bosch F, Papp K, et al. Long-term efficacy and safety of risankizumab for active psoriatic arthritis: 148-week results from the KEEPsAKE 2 trial. Poster presented at: American College of Rheumatology Convergence; November 10-15, 2023; San Diego, CA.
Data on file, AbbVie Inc. ABVRRTI81133.
Data on file, AbbVie Inc. ABVRRTI81262.

US-SKZR-260007

REFERENCES

Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225-231. doi:10.1136/annrheumdis-2021-221019
Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81(3):351-358. doi:10.1136/annrheumdis-2021-221048

US-SKZR-260007

REFERENCES

SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225-231. doi:10.1136/annreheumdis-2021-221019
Kristensen LE, Papp K, White D, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the KEEPsAKE 1 and KEEPsAKE 2 trials. Poster presented at: 31st European Academy of Dermatology and Venereology (EADV) Congress; September 7-10, 2022; hybrid.

US-SKZR-260007

REFERENCES

SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022:81(3):351-358. doi:10.1136/annrheumdis-2021-221048
Data on file, AbbVie Inc. ABVRRTI81322.
Data on file, AbbVie Inc. ABVRRTI83699.

US-SKZR-260007

REFERENCES

SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022;81(2):225-231. doi:10.1136/annreheumdis-2021-221019
Kristensen LE, Papp K, White D, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the KEEPsAKE 1 and KEEPsAKE 2 trials. Poster presented at: 31st European Academy of Dermatology and Venereology (EADV) Congress; September 7-10, 2022; hybrid.

US-SKZR-260007

REFERENCES

SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
Östör A, Van den Bosch F, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022:81(3):351-358. doi:10.1136/annrheumdis-2021-221048
Data on file, AbbVie Inc. ABVRRTI81322.
Data on file, AbbVie Inc. ABVRRTI83699.

US-SKZR-260007

REFERENCES

SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
Data on file, AbbVie Inc. ABVRRTI83699.

US-SKZR-260007

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Hypersensitivity Reactions, Infections, Tuberculosis (TB), Hepatotoxicity, Immunizations

Hypersensitivity Reactions

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

Hypersensitivity Reactions, Infections, Tuberculosis (TB), Hepatotoxicity, Immunizations

Hypersensitivity Reactions

		KEEPsAKE 1		KEEPsAKE 2
		PLACEBO (n=481)	SKYRIZI (n=483)	PLACEBO (n=219)	SKYRIZI (n=224)
Demographics	Sex (Female) n (%)	247 (51.4)	231 (47.8)	120 (54.8)	124 (55.4)
	Race (White) n (%)	451 (93.8)	454 (94.0)	210 (95.9)	218 (97.3)
	Age (Years) median (range)	52 (22-79)	52 (20-85)	52 (24-83)	53 (23-84)
	BMI (kg/m²) mean (SD)	30.3 (6.2)	30.7 (6.4)	31.2 (6.8)	31.5 (8.0)
Disease Characteristics	PsA-mTSS mean (SD)	13.5 (29.0)	13.0 (29.9)	—	—
	Presence of Dactylitis (LDI>0) n (%)	147 (30.6)	148 (30.6)	57 (26.3)	40 (17.9)
	Presence of Enthesitis (LEI>0) n (%)	290 (60.3)	297 (61.5)	158 (72.1)	147 (65.6)
	Tender Joint Count^a mean (SD)	20.5 (12.8)	20.8 (14.1)	22.3 (13.8)	22.8 (14.9)
	Swollen Joint Count^b mean (SD)	12.2 (8.0)	12.1 (7.8)	13.6 (9.0)	13.0 (8.7)
	BSA of Psoriatic Plaques ≥3% n (%)	272 (56.5)	273 (56.5)	119 (54.3)	123 (54.9)
	PASI (for BSA ≥3) mean (SD)	10.0 (10.4)	10.9 (10.1)	8.4 (9.9)	7.7 (6.7)
	Disease duration (Years) mean (SD)	7.1 (7.7)	7.1 (7.0)	8.2 (8.3)	8.2 (8.2)
	HAQ-DI mean (SD)	1.2 (0.7)	1.2 (0.7)	1.1 (0.6)	1.1 (0.6)
Biologic experience	Prior Biologics ≥1 n (%)	—	—	101 (46.1)	105 (46.9)
Concomitant medication	Concomitant csDMARD at Baseline n (%)
	Any csDMARD	364 (75.7)	366 (75.8)	129 (58.9)	141 (62.9)
	MTX	315 (65.5)	314 (65.0)	99 (45.2)	110 (49.1)
	csDMARD Other Than MTX	49 (10.2)	52 (10.8)	30 (13.7)	31 (13.8)
	None	117 (24.3)	117 (24.2)	90 (41.1)	83 (37.1)
	Oral Corticosteroids at Baseline n (%)	87 (18.1)	101 (20.9)	22 (10.0)	28 (12.5)
	NSAIDs at Baseline n (%)	314 (65.3)	296 (61.3)	145 (66.2)	141 (62.9)

	SKYRIZI (n=224)			Placebo (n=219)
	Baseline	Mean Change at Week 24 (RCT)	Mean Change at Week 304 (OLE)	Baseline	Mean Change at Week 24 (RCT)
Number of Swollen Joints (0-66)	13.0	-9.1	-11.6 (n=134)	13.6	-6.5
Number of Tender Joints (0-68)	22.8	-13.0	-19.0 (n=134)	22.3	-8.3
Patient's Assessment of Pain (0-100 VAS)	55.0	-15.3	-25.4 (n=129)	57.0	-8.7
Patient's Global Assessment of Disease Activity (0-100 VAS)	56.2	-17.7	-28.1 (n=129)	56.2	-8.7
Physician's Global Assessment of Disease Activity (0-100 VAS)	63.0	-35.5	-53.5 (n=120)	60.7	-21.3
HAQ-DI* (0-3 scale, where 0=no difficulty, 3=inability to perform)	1.1	-0.2	-0.4 (n=129)	1.1	-0.1
hs-CRP (mg/L)	7.4	-1.8	-2.3 (n=127)	8.2	-0.5

SUSTAINED JOINT SYMPTOM RELIEF

SELECT BASELINE CHARACTERISTICS IN SKYRIZI CLINICAL TRIALS1-3

SUSTAINED RELIEF IN JOINTS WITH RESULTS UP TO ~6 YEARS

ACR20/50/70 RESPONSE RATES FOR csDMARD-IR PATIENTS SUSTAINED AT ~6 YEARS6,7

IMPROVEMENTS IN ACR COMPONENTS OF DISEASE ACTIVITY AT WEEK 24 (MMRM) AND ~6 YEARS (AO)1,7

DO YOUR PsA PATIENTS HAVE SKIN INVOLVEMENT?

COMPLETE RESOLUTION OF ENTHESITIS & DACTYLITIS2,†

INTEGRATED RESULTS FROM KEEPsAKE 1: csDMARD-IR, AND KEEPsAKE 2: MIXED POPULATION (~50% csDMARD-IR, ~50% Bio-IR): LEI AND LDI OVER TIME6,8

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)1

SELECT BASELINE CHARACTERISTICS IN SKYRIZI CLINICAL TRIALS^1-3

ACR20/50/70 RESPONSE RATES FOR csDMARD-IR PATIENTS SUSTAINED AT ~6 YEARS^6,7

IMPROVEMENTS IN ACR COMPONENTS OF DISEASE ACTIVITY 
AT WEEK 24 (MMRM) AND ~6 YEARS (AO)^1,7

COMPLETE RESOLUTION OF ENTHESITIS & DACTYLITIS^2,†

INTEGRATED RESULTS FROM KEEPsAKE 1: csDMARD-IR, AND KEEPsAKE 2: MIXED POPULATION (~50% csDMARD-IR, ~50% Bio-IR): LEI AND LDI OVER TIME^6,8

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR SKYRIZI® (risankizumab-rzaa)¹